Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2013

01-12-2013 | Short Communication

An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs

Author: Vincent Launay-Vacher

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2013

Login to get access

Abstract

Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients’ care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a valid alternative to the IV, both in terms of efficacy and safety. This results in substantial time savings for patients, pharmacists, physicians and nursing staff, with a healthcare professionals’ and patients’ preference largely going to SC. In addition, the possibility to treat patients with poor venous access or to spare patients’ venous capital when necessary may also be of interest.
Literature
1.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef
2.
Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23:4265–4274PubMedCrossRef
3.
Smith I, Procter M, Gelber RD et al (2007) 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRef
4.
Goldhirsch A, Piccart M, Procter M et al (2012) HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. European Society of Medical Oncology Congress 2012; Vienna, Austria: Abstract LBA6
5.
Goldhirsch A, Piccart M, Procter M et al (2012) HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. In: San Antonio breast cancer symposium 2012; San Antonio, TX, USA: Abstract S5-2
6.
Thomas JR, Yocum RC, Haller MF, von Gunten CF (2007) Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 10(6):1312–1320PubMedCrossRef
7.
Frost GI (2007) Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4(4):427–440PubMedCrossRef
8.
Harb G, Lebel F, Battikha J, Thackara JW (2010) Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 26(2):279–288PubMedCrossRef
9.
Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J (2009) The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage 38(5):663–672PubMedCrossRef
10.
Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11):2645–2668PubMedCrossRef
11.
Wang DD, Zhang S, Zhao H, Men AY, Parivar K (2009) Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 49(9):1012–1024PubMedCrossRef
12.
Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B (2012) Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2012 Feb 22. [Epub ahead of print]
13.
Ismael G, Hegg R, Muehlbauer S et al (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13(9):869–878PubMedCrossRef
14.
Jackisch C, Dank M, Frasci G, et al. (2012) Additional safety results of HannaH: a phase III randomised, open-label, international study of the subcutaneous formulation of trastuzumab (H) in HER2-positive early breast cancer patients. European Society of Medical Oncology Congress 2012; Vienna, Austria: Abstract 271P
15.
Melichar B, Stroyakovskiy D, Seok Ahn J et al (2012) Pathological complete response to trastuzumab subcutaneous fixed-dose formulation in the HannaH study: Subgroup analysis of patient demographics and tumour characteristics and influence of body weight and serum trough concentration of trastuzumab. European Society of Medical Oncology Congress 2012; Vienna, Austria: Abstract 254PD
16.
17.
Samanta K, Nawaz S, Lord S, McNamara S, Diment V (2013) Cost savings with Hercveptin® (trastuzumab) subcutaneous vs intravenous administration: a time & motion study. In: St Gallen international breast cancer conference, St Gallen, Switzerland, 2013. Poster no. 282
18.
De Cock E, Semiglazov V, Lopez-Vivanco G, Verma S, Pivot X, Gligorov J, Hauser N, Urspruch A, Kritikou P, Knoop A (2013) Time savings with trastuzumab subcutaneous vs. intravenous administration: a time and motion study. In: St Gallen international breast cancer conference, St Gallen, Switzerland, 2013. Poster no. 209
19.
Pivot X, Gligorov J, Müller V, Verma S, Knoop A, Curigliano G, Jenkins V, Scotto N, Osborne S, Fallowfield L (2013) Patient preference for subcutaneous versus intravenous adjuvant trastuzumab: results of the Prefher study. In: St Gallen International breast cancer conference, St Gallen, Switzerland, 2013. Poster no. 207
20.
Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L (2013) Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study; for the PrefHer Study Group. Lancet Oncol;[Epub ahead of print]
21.
Allen PB, Lindsay H, Tham TC (2010) How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 10:1PubMedCrossRef
22.
Scarpato S, Antivalle M, Favalli EG et al (2010) Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology 49(2):289–294PubMedCrossRef
Metadata
Title
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs
Author
Vincent Launay-Vacher
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2289-4

Other articles of this Issue 6/2013

Cancer Chemotherapy and Pharmacology 6/2013 Go to the issue

Original Article

A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer

Original Article

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study

Review Article

The role of antioxidants in the era of cardio-oncology

Original Article

Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases

Original Article

A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401

Original Article

Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits